[The effects of intrapleural anti-TNFalpha antibody on chemical pleurodesis induced by talc slurry or doxycycline].
OBJECTIVE
To determine whether the intrapleural injection of TNFalpha neutralizing Fab antibody fragment (anti-TNFalpha Fab) would prevent the pleurodesis that occurs after the intrapleural injection of talc or doxycycline.


METHODS
In a randomized blinded placebo controlled study, 34 New Zealand white rabbits were given 400 mg/kg talc or 10 mg/kg doxycycline intrapleurally as a sclerosant via a chest tube. Half of the rabbits in each group were also given polyclonal affinity purified anti-TNFalpha Fab 2 000 units or saline as placebo immediately before and 12 hours after the injection of the sclerosants. Chest tube were aspirated at 12 hours intervals until their removal at 4 days. Rabbits were sacrificed at 28 days. The pleural fluid volume, cell counts, LDH and pleurodesis scores were compared among groups.


RESULTS
Both talc and doxycycline produced an exudative pleural effusion. The pleural fluid volume and LDH levels were significantly greater in the doxycycline group than talc group. However, the pleural fluid leukocyte counts in talc group were higher than doxycycline group. The administration of anti-TNFalpha Fab had no significant effect on pleural fluid volume, LDH or leukocyte counts in either groups. However, the intrapleural administration of anti-TNFalpha Fab results in a significant decrease in the pleurodesis score for the talc group than doxycycline group (1.8 +/- 0.9 vs 3.2 +/- 0.8). In contrast the pleurodesis score was virtually identical in the doxycycline group with (3.5 +/- 0.5) and without (3.4 +/- 0.7) anti-TNFalpha Fab.


CONCLUSIONS
The intrapleural administration of anti-TNFalpha Fab diminishes the pleurodesis induced by talc but not that which results from doxycycline. These findings suggest that different mechanisms are involed with the two different sclerosants.
Cheng
D
D
First affiliated Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou 510080, China.
Xie
C
C
Light
R W
RW
D000818:Animals; D004318:Doxycycline / Q000494:pharmacology*; D004347:Drug Interactions; D005122:Exudates and Transudates / Q000187:drug effects; D007140:Immunoglobulin Fab Fragments / Q000276:immunology / Q000494:pharmacology*; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D007958:Leukocyte Count; D023421:Models, Animal; D018700:Pleurodesis; D011817:Rabbits; D013627:Talc / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D007140:Immunoglobulin Fab Fragments; D014409:Tumor Necrosis Factor-alpha; D013627:Talc; D007770:L-Lactate Dehydrogenase; D004318:Doxycycline